{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:21:09Z","timestamp":1793974869707,"version":"4.8.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Dar\u00e9 Bioscience"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the efficacy of topical sildenafil cream, 3.6% among healthy premenopausal women with female sexual arousal disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a phase 2b, exploratory, randomized, placebo-controlled, double-blind study of sildenafil cream. Coprimary efficacy endpoints were the change from baseline to week 12 in the Arousal Sensation domain of the SFQ28 (Sexual Function Questionnaire) and question 14 of the FSDS-DAO (Female Sexual Distress Scale\u2014Desire, Arousal, Orgasm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Two hundred women with female sexual arousal disorder were randomized to sildenafil cream (n=101) or placebo cream (n=99). A total of 174 participants completed the study (sildenafil 90, placebo 84). Among the intention-to-treat (ITT) population, which included women with only female sexual arousal disorder and those with female sexual arousal disorder with concomitant sexual dysfunction diagnoses or genital pain, although the sildenafil cream group demonstrated greater improvement in the SFQ28 Arousal Sensation domain scores, there were no statistically significant differences between sildenafil and placebo cream users in the coprimary and secondary efficacy endpoints. An exploratory post hoc subset of the ITT population with an enrollment diagnosis of female sexual arousal disorder with or without concomitant decreased desire randomized to sildenafil cream reported significant increases in their SFQ28 Arousal Sensation domain score (least squares mean 2.03 [SE 0.62]) compared with placebo cream (least squares mean 0.08 [SE 0.71],\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.04). This subset achieved a larger mean improvement in the SFQ28 Desire and Orgasm domain scores. This subset population also had significantly reduced sexual distress and interpersonal difficulties with sildenafil cream use as measured by FSDS-DAO questions 3, 5, and 10 (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2264.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Topical sildenafil cream improved outcomes among women with female sexual arousal disorder, most significantly in those who did not have concomitant orgasmic dysfunction. In particular, in an exploratory analysis of a subset of women with female sexual arousal disorder with or without concomitant decreased desire, topical sildenafil cream increased sexual arousal sensation, desire, and orgasm and reduced sexual distress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT04948151.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000005648","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:00:29Z","timestamp":1718730029000},"page":"144-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder"],"prefix":"10.1097","volume":"144","author":[{"given":"Isabella","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Ries","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hatheway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Dart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Paige","family":"Brainard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"R1-20260826","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.sxmr.2020.05.001","article-title":"The evolution of the female sexual disorder\/dysfunction definitions, nomenclature, and classifications: a review of DSM, ICSM, ISSWSH, and ICD","volume":"9","author":"Parish","year":"2021","journal-title":"Sex Med Rev"},{"key":"R2-20260826","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10508-009-9535-1","article-title":"The DSM diagnostic criteria for female sexual arousal disorder","volume":"39","author":"Graham","year":"2010","journal-title":"Arch Sex Behav"},{"key":"R3-20260826","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2307\/2136095","article-title":"A political history of the national sex survey of adults","volume":"26","author":"Laumann","year":"1994","journal-title":"Fam Plann Perspect"},{"key":"R4-20260826","first-page":"133","article-title":"Female sexual interest\/arousal disorder: history of diagnostic considerations and their implications for clinical practice","volume":"37","author":"Witherow-Parkanyi","year":"2022","journal-title":"Psychiatr Hung"},{"key":"R5-20260826","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/GRF.0b013e3181bf4982","article-title":"Diagnosis and treatment of female sexual arousal disorder","volume":"52","author":"Jayne","year":"2009","journal-title":"Clin Obstet Gynecol"},{"key":"R6-20260826","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1345\/aph.1G471","article-title":"Use of sildenafil for female sexual dysfunction","volume":"40","author":"Shields","year":"2006","journal-title":"Ann Pharmacother"},{"key":"R7-20260826","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrurol.2009.25","article-title":"Sildenafil citrate for female sexual arousal disorder: a future possibility?","volume":"6","author":"Schoen","year":"2009","journal-title":"Nat Rev Urol"},{"key":"R8-20260826","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1345\/aph.1L691","article-title":"Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction","volume":"43","author":"Brown","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R9-20260826","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1743-6109.2009.01599.x","article-title":"Phosphodiesterase type 5 inhibitors and female sexual response: faulty protocols or paradigms?","volume":"7","author":"Chivers","year":"2010","journal-title":"J Sex Med"},{"issue":"suppl 4","key":"R10-20260826","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1038\/sj.ijir.3900596","article-title":"Female sexual arousal disorder: new insights","volume":"12","author":"Goldstein","year":"2000","journal-title":"Int J Impot Res"},{"key":"R11-20260826","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1093\/jsxmed\/qdac043","article-title":"Symptoms and associated impact in pre- and postmenopausal women with sexual arousal disorder: a concept elicitation study","volume":"20","author":"Symonds","year":"2023","journal-title":"J Sex Med"},{"key":"R12-20260826","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jama.2008.694","article-title":"Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial","volume":"300","author":"Nurnberg","year":"2008","journal-title":"JAMA"},{"key":"R13-20260826","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1097\/01.ju.0000090966.74607.34","article-title":"Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study","volume":"170","author":"Berman","year":"2003","journal-title":"J Urol"},{"key":"R14-20260826","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2217\/whe-2016-0018","article-title":"Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial","volume":"12","author":"Clayton","year":"2016","journal-title":"Womens Health (Lond)"},{"key":"R15-20260826","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/gme.0b013e31819e85c6","article-title":"Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"R16-20260826","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1743-6109.2011.02626.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study","volume":"9","author":"Derogatis","year":"2012","journal-title":"J Sex Med"},{"key":"R17-20260826","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1743-6109.2011.02595.x","article-title":"Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study","volume":"9","author":"Thorp","year":"2012","journal-title":"J Sex Med"},{"key":"R18-20260826","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0090-4295(02)01663-1","article-title":"Type 5 phosphodiesterase expression in the human vagina","volume":"60","author":"D'Amati","year":"2002","journal-title":"Urology"},{"key":"R19-20260826","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11934-003-0027-x","article-title":"Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists","volume":"4","author":"Francis","year":"2003","journal-title":"Curr Urol Rep"},{"key":"R20-20260826","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00345-005-0015-5","article-title":"Phosphodiesterase inhibitors in female sexual dysfunction","volume":"23","author":"Mayer","year":"2005","journal-title":"World J Urol"},{"key":"R21-20260826","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.urology.2005.11.055","article-title":"Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study","volume":"67","author":"Oelke","year":"2006","journal-title":"Urology"},{"key":"R22-20260826","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1006\/bbrc.1998.9206","article-title":"Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle","volume":"249","author":"Park","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R23-20260826","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1019831906508","article-title":"Biochemical and physiological mechanisms of female genital sexual arousal","volume":"31","author":"Traish","year":"2002","journal-title":"Arch Sex Behav"},{"key":"R24-20260826","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00345-005-0014-6","article-title":"In vitro functional responses of isolated human vaginal tissue to selective phosphodiesterase inhibitors","volume":"23","author":"Uckert","year":"2005","journal-title":"World J Urol"},{"key":"R25-20260826","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/j.1743-6109.2007.00595.x","article-title":"Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissues","volume":"4","author":"Uckert","year":"2007","journal-title":"J Sex Med"},{"key":"R26-20260826","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ijir.2011.29","article-title":"Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5)","volume":"23","author":"Uckert","year":"2011","journal-title":"Int J Impot Res"},{"key":"R27-20260826","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1743-6109.2007.00490.x","article-title":"Immunohistochemical description of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human labia minora","volume":"4","author":"Uckert","year":"2007","journal-title":"J Sex Med"},{"key":"R28-20260826","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0024-3205(00)00596-8","article-title":"Sildenafil relaxes rabbit clitoral corpus cavernosum","volume":"67","author":"Vemulapalli","year":"2000","journal-title":"Life Sci"},{"key":"R29-20260826","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/0092623X.2019.1623356","article-title":"Sexual motivation in couples coping with female sexual interest\/arousal disorder: a comparison with control couples","volume":"45","author":"Bockaj","year":"2019","journal-title":"J Sex Marital Ther"},{"key":"R30-20260826","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.sxmr.2021.07.003","article-title":"A systematic literature review of health-related quality of life measures for women with hypoactive sexual desire disorder and female sexual interest\/arousal disorder","volume":"10","author":"Lim-Watson","year":"2022","journal-title":"Sex Med Rev"},{"key":"R31-20260826","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/jsm.12189","article-title":"Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial","volume":"10","author":"Katz","year":"2013","journal-title":"J Sex Med"},{"key":"R32-20260826","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1089\/jwh.2018.7516","article-title":"Flibanserin for premenopausal hypoactive sexual desire disorder: pooled analysis of clinical trials","volume":"28","author":"Simon","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"key":"R33-20260826","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R34-20260826","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/AOG.0000000000003500","article-title":"Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials","volume":"134","author":"Kingsberg","year":"2019","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:03:27Z","timestamp":1787742207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005648"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005648","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"2024-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}